Showing results (251-260 of 268) with videos related to

Sort By:
Pageof 27
Radiology|August 15, 2012
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activityChristina Messiou, Matthew Orton, Joo Ern Ang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.
The Lancet. Oncology|January 8, 2020
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendationMatthias Guckenberger, Yolande Lievens, Angelique B Bouma, et al.
Insights Into Imaging|August 31, 2019
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)Nandita M deSouza, Eric Achten, Angel Alberich-Bayarri, et al.
Nature Communications|September 25, 2020
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancerHemant M Kocher, Bristi Basu, Fieke E M Froeling, et al.
Circulation. Cardiovascular Genetics|October 20, 2011
A gene expression signature that classifies human atherosclerotic plaque by relative inflammation statusOscar Puig, Jeffrey Yuan, Sergey Stepaniants, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studiesTimothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkersTimothy A Yap, Li Yan, Amita Patnaik, et al.
Frontiers in Oncology|January 27, 2022
Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint PaperLaure Fournier, Lioe-Fee de Geus-Oei, Daniele Regge, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
Pageof 27